Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer.

ABSTRACT: The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).

SUBMITTER: Tkac J 

PROVIDER: S-EPMC6388024 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature